住院姑息治疗与终末期肾病患者医疗利用及出院结局的关联
该研究分析2012至2013年Medicare终末期肾病患者,按住院期间是否死亡分层,用倾向评分匹配比较接受住院姑息治疗与常规治疗者的医疗利用和出院结局。结果显示,死亡组姑息治疗与更短住院时间和更低费用相关;存活组住院时间无差异但费用更高,出院后临终关怀使用更多、再住院更少。
要点
- 住院姑息治疗在终末期肾病患者中开展不足1%。
- 住院期间死亡者接受姑息治疗与住院时间缩短4.2天、费用降低相关。
- 存活出院者接受姑息治疗与更高临终关怀使用和更低再住院相关。
核心结论
- 住院期间死亡的终末期肾病患者接受姑息治疗与更短住院时间和更低费用相关。
- 存活出院者接受姑息治疗住院时间无差异但费用更高,出院后临终关怀使用显著增加且再住院减少。
研究设计与样本
- 基于2012至2013年Medicare终末期肾病患者,按住院期间是否死亡分层,使用倾向评分匹配接受住院姑息治疗者与常规治疗者。
主要发现
- 死亡队列(n=1308)中,姑息治疗与住院时间缩短21%(-4.2天,95%CI -5.6至-2.9天)和住院费用降低14%(-$10,698,95%CI -$17,553至-$3,843)相关。
- 非死亡队列(n=5024)中,姑息治疗与住院时间无差异(0.4天,95%CI -0.3至1.0天)和住院费用升高11%($4,275,95%CI $1,984至$6,567)相关。
- 出院后30天内,接受住院姑息治疗者临终关怀入组可能性更高(HR 8.3,95%CI 6.6至10.5),再住院可能性更低(HR 0.8,95%CI 0.7至0.9)。
临床怎么用
- 对住院的终末期肾病患者,尤其预期住院期间死亡者,可考虑姑息治疗以缩短住院时间并降低费用。
- 对存活出院者,姑息治疗虽增加住院费用,但可促进临终关怀使用并减少再住院。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Palliative care may improve quality of life and reduce the cost of care for patients with chronic illness, but utilization and cost implications of palliative care in ESKD have not been evaluated. We sought to determine the association of inpatient palliative care with health care utilization and postdischarge outcomes in ESKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In analyses stratified by whether patients died during the index hospitalization, we identified Medicare beneficiaries with ESKD who received inpatient palliative care, ascertained by provider specialty codes, between 2012 and 2013. These patients were matched to hospitalized patients who received usual care using propensity scores. Primary outcomes were length of stay and hospitalization costs. Secondary outcomes were 30-day readmission and hospice enrollment. RESULTS: Inpatient palliative care occurred in <1% of hospitalizations lasting >2 days. Among the decedent cohort (n=1308), inpatient palliative care was associated with a 21% shorter length of stay (-4.2 days; 95% confidence interval, -5.6 to -2.9 days) and 14% lower hospitalization costs (-$10,698; 95% confidence interval, -$17,553 to -$3843) compared with usual care. Among the nondecedent cohort (n=5024), inpatient palliative care was associated with no difference in length of stay (0.4 days; 95% confidence interval, -0.3 to 1.0 days) and 11% higher hospitalization costs ($4275; 95% confidence interval, $1984 to $6567) compared with usual care. In the 30-day postdischarge period, patients who received inpatient palliative care had higher likelihood of hospice enrollment (hazard ratio, 8.3; 95% confidence interval, 6.6 to 10.5) and lower likelihood of rehospitalization (hazard ratio, 0.8; 95% confidence interval, 0.7 to 0.9). CONCLUSIONS: Among patients with ESKD who died in the hospital, inpatient palliative care was associated with shorter hospitalizations and lower costs. Among those who survived to discharge, inpatient palliative care was associated with no difference in length of stay and higher hospitalization costs but markedly higher hospice use and fewer readmissions after discharge.
引用
- Chettiar A, Montez-Rath M, Liu S, et al. Association of Inpatient Palliative Care with Health Care Utilization and Postdischarge Outcomes among Medicare Beneficiaries with End Stage Kidney Disease. Clin J Am Soc Nephrol. 2018. PMID: 30026286. doi:10.2215/CJN.00180118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。